Announcements
Projects
Orgs
Project Post
Articles 15
Votes 0
The Pharma Letter

Authors 1

The Pharma Letter
First pill for dengue - JNJ-1802 - shows promise - The Pharma Letter
>1y
A decades-long program to develop the first new vaccine for pulmonary tuberculosis in a century has received a half-billion dollar funding boost. British drugmaker GSK (LSE: GSK) has been working on the jab, dubbed M72, since it picked up rights to the candidate through its 2005 purchase of American biotech Corixa. While the vaccine has shown 54% effectiveness in a Phase II trial enrolling around ... - The Pharma Letter
~2y
Initial safety and immunogenicity results from a Phase III trial of Bavarian Nordic's (OMX: BAVA) chikungunya virus vaccine candidate have been announced. The candidate is known as PXVX0317. The company said that the study has already met its primary efficacy endpoints, with a strong induction of chikungunya virus neutralizing antibodies having been observed in 87% of those receiving the ... - The Pharma Letter
~2y
Pfizer and GSK to battle for share of new RSV vaccine market - The Pharma Letter
~2y
The UK Department of Health and Social Care (DHSC) proposes £39 million ($48.5 million) of funding for antimicrobial resistance (AMR) research through the Global AMR Innovation Fund (GAMRIF). Of this new funding package, up to £24 million over four years has been awarded to bolster the UK's partnership with CARB-X – a global AMR research initiative – to support the continued early ... - The Pharma Letter
~2y
India's drug panel to review mRNA Omicron vaccine booster amidst COVID-19 surge - The Pharma Letter
>2y
Danish diabetes care giant Novo Nordisk's (NOV: N) has been impacted by supply chain issues, for the production of semaglutide, the active ingredient of its obesity drug Wegovy, as well as diabetes drugs Ozempic and Rybelsus. However, the company recently assured that US supplies were back on track, and this month it was revealed that Wegovy would be available on high-street pharmacies in the ... - The Pharma Letter
>2y
FDA expands use of Sanofi's Adacel vaccine - The Pharma Letter
>2y
UK industry and NHS members promote better access to innovation - The Pharma Letter
>2y
BRIEF—New FDA label approval for Wegovy - The Pharma Letter
>2y
Nubeqa now available for mHS prostate cancer patients in England - The Pharma Letter
>2y
India to soon have monkeypox vaccine - The Pharma Letter
>2y
BRIEF—NIH starts enrollment for US clinical trial evaluating TPOXX for - The Pharma Letter
almost3y
German drugmaker STADA Arzneimittel (SAZ: Xetra) is broadening its offering to patients, pharmacists and physicians in Europe by introducing abiraterone acetate 500mg film-coated tablets in 21 European countries. Used for treating metastatic prostate cancer, abiraterone adds to STADA's comprehensive oncology offering that spans oral and injectable medicines, including biological agents such as ... - The Pharma Letter
almost3y
The European Medicines Agency's (EMA) human medicines committee (CHMP) has endorsed the recommendation of the Pharmacovigilance Risk Assessment Committee (PRAC) in concluding that the benefits of medicines containing nomegestrol or chlormadinone outweigh the risks, provided new measures are taken to minimize the risk of meningioma. Medicines containing nomegestrol or ... - The Pharma Letter
almost3y